Literature DB >> 26629433

Rebuttal from Ms Woodford and Dr Senthi.

Katrina Woodford1, Sashendra Senthi1.   

Abstract

Year:  2015        PMID： 26629433      PMCID： PMC4630523          DOI： 10.3978/j.issn.2218-6751.2015.08.11

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  8 in total

1.  LungTech, an EORTC Phase II trial of stereotactic body radiotherapy for centrally located lung tumours: a clinical perspective.

Authors:  S Adebahr; S Collette; E Shash; M Lambrecht; C Le Pechoux; C Faivre-Finn; D De Ruysscher; H Peulen; J Belderbos; R Dziadziuszko; C Fink; M Guckenberger; C Hurkmans; U Nestle
Journal:  Br J Radiol       Date:  2015-04-15       Impact factor: 3.039

2.  Pulmonary atelectasis after stereotactic ablative radiotherapy for a central lung tumor.

Authors:  Sashendra Senthi; Eric F Ullmann; Suresh Senan
Journal:  J Thorac Oncol       Date:  2013-11       Impact factor: 15.609

3.  Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.

Authors:  Aadel A Chaudhuri; Chad Tang; Michael S Binkley; Michelle Jin; Jacob F Wynne; Rie von Eyben; Wendy Y Hara; Nicholas Trakul; Billy W Loo; Maximilian Diehn
Journal:  Lung Cancer       Date:  2015-05-04       Impact factor: 5.705

4.  Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer.

Authors:  Frank J Lagerwaard; Neil K Aaronson; Chad M Gundy; Cornelis J A Haasbeek; Ben J Slotman; Suresh Senan
Journal:  J Thorac Oncol       Date:  2012-07       Impact factor: 15.609

5.  Massive haemoptysis after radiotherapy in inoperable non-small cell lung carcinoma: is endobronchial brachytherapy really a risk factor?

Authors:  J A Langendijk; M K Tjwa; J M de Jong; G P ten Velde; E F Wouters
Journal:  Radiother Oncol       Date:  1998-11       Impact factor: 6.280

6.  Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer.

Authors:  Noëlle C van der Voort van Zyp; Jean-Briac Prévost; Bronno van der Holt; Cora Braat; Robertus J van Klaveren; Peter M Pattynama; Peter C Levendag; Joost J Nuyttens
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-26       Impact factor: 7.038

7.  Central thoracic lesions treated with hypofractionated stereotactic body radiotherapy.

Authors:  Michael T Milano; Yuhchyau Chen; Alan W Katz; Abraham Philip; Michael C Schell; Paul Okunieff
Journal:  Radiother Oncol       Date:  2009-03-28       Impact factor: 6.280

8.  Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer.

Authors:  Donald M Cannon; Minesh P Mehta; Jarrod B Adkison; Deepak Khuntia; Anne M Traynor; Wolfgang A Tomé; Richard J Chappell; Ranjini Tolakanahalli; Pranshu Mohindra; Søren M Bentzen; George M Cannon
Journal:  J Clin Oncol       Date:  2013-10-21       Impact factor: 44.544
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.